Sarepta Therapeutics (SRPT) has risen sharply, recording gains of 20.16% in the past 4 weeks. However, the stock has corrected -7.78% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 15.13% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has recorded a 20-day Moving Average of 8.07% and the 50-Day Moving Average is 10.68%.
Sarepta Therapeutics (NASDAQ:SRPT): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $20.23 and $19.71 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $20.91. The buying momentum continued till the end and the stock did not give up its gains. It closed at $20.86, notching a gain of 2.05% for the day. The total traded volume was 2,560,344 . The stock had closed at $20.44 on the previous day.
The company Insiders own 10.9% of Sarepta Therapeutics shares according to the proxy statements. Institutional Investors own 73.5% of Sarepta Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of 4.44%. In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Sarepta Therapeutics, Inc., Behrens M Kathleen, had purchased 75,000 shares in a transaction dated on March 14, 2016. The transaction was executed at $15.54 per share with total amount equaling $1,165,500.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.